TY - JOUR T1 - The Effect of GDP and Distance on Timing of COVID-19 Spread in Chinese Provinces in 2020 JF - medRxiv DO - 10.1101/2020.07.19.20157354 SP - 2020.07.19.20157354 AU - Alice Kuan AU - Mingxin Chen AU - David Bishai Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/21/2020.07.19.20157354.abstract N2 - The geographical spread of COVID-19 across China’s provinces provides the opportunity for retrospective analysis on contributors to the timing of the spread. Highly contagious diseases need to be seeded into populations and we hypothesized that greater distance from the epicenter in Wuhan, as well as higher province-level GDP per capita, would delay the time until a province detected COVID-19 cases. To test this hypothesis, we used province-level socioeconomic data such as GDP per capita and percentage of the population aged over 65, distance from the Wuhan epicenter, and health systems capacity in a Cox proportional hazards analysis of the determinants of each province’s time until epidemic start. The start was defined by the number of days it took for each province to reach thresholds of 3, 5, 10, or 100 cases. We controlled for the number of hospital beds and physicians as these could influence the speed of case detection. Surprisingly, none of the explanatory variables had a statistically significant effect on the time it took for each province to get its first cases; the timing of COVID-19 spread appears to have been random with respect to distance, GDP, demography, and the strength of the health system. Looking to other factors, such as travel, policy, and lockdown measures, could provide additional insights on realizing most critical factors in the timing of spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding received for this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is not human subjects research, so IRB approval was not needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data on cumulative COVID-19 cases in Chinese provinces is publicly available from the JHU CSSE Github repository. Data on province-level variables is available from Beijing University. https://github.com/CSSEGISandData/COVID-19 ER -